Moneycontrol PRO
Open App
you are here: HomeNewsCovaxin
covaxin

Hyderabad-based pharmaceutical firm Bharat Biotech in collaboration with the Indian Council of Medical Research - National Institute of Virology developed an inactivated virus-based COVID-19 vaccine and named it Covaxin. This has been code-named as BBV152. According to CoWin statistics, till October 2021, around 110.6 million people in India have received Covaxin. Also, the World Health Organisation on November 3, 2021, validated the vaccine for emergency use and Covaxin has been granted emergency use approval in 13 countries as of January 31, 2022. Speaking about the efficacy of Covaxin, the vaccine has been proved to be 64 percent effective against asymptomatic cases, 78 percent effective against symptomatic disease, 93 percent effective against severe disease, and 65 percent effective against the Delta variant. India's Central Drugs Standard Control Organization (CDSCO) recommended permission for Covaxin on January 2, 2021, which was granted the next day. The government approved Bharat Biotech's Covaxin for usage on children between 2 and 18 years of age on October 12, 2021. Apart from India, the vaccine was also approved for emergency use in Iran, Zimbabwe, Nepal, Mexico, Philippines, Guatemala, Nicaragua, Guyana, Venezuela and Botswana. In terms of foreign shipment, Mauritius received its first commercial supply of Covaxin on March 18, 2021. Similarly, Paraguay received 100,000 doses of Covaxin on March 29, 2021 and Argentina agreed to buy 10 million doses of Covaxin and administer them to its citizens in June 2021. More

Jump to
  • Can Bharat Biotech's intranasal vaccine prevent COVID-19 infection and transmission?  Aug 16, 2022 02:12 PM IST

    Can Bharat Biotech's intranasal vaccine prevent COVID-19 infection and transmission? 

    With Bharat Biotech completing clinical trials of its vaccine candidate, hopes have been raised about the availability of intranasal vaccine as a booster dose just as the number of daily Covid-19 cases and test positivity rate in parts of India have started surging over the last few weeks.  

  • Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield Aug 10, 2022 11:13 AM IST

    Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

    This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country.

  • Covaxin booster doses effective against variants, shows study Jul 20, 2022 05:54 PM IST

    Covaxin booster doses effective against variants, shows study

    The findings of the study have been published in the high-impact scientific journal Nature.

  • Political will at the top and community participation at the bottom drove India's COVID-19 vaccination campaign: Dr N K Arora Jul 18, 2022 12:19 PM IST

    Political will at the top and community participation at the bottom drove India's COVID-19 vaccination campaign: Dr N K Arora

    On July 17, India administered its 2 billionth COVID-19 vaccine dose, 18 months after the mammoth vaccination drive against coronavirus was launched. Of the total doses administered, 51 percent doses were given to women and 71 percent vaccination centres were in rural areas

  • Moneycontrol Selects: Top stories this evening Jul 08, 2022 06:22 PM IST

    Moneycontrol Selects: Top stories this evening

    Our specially curated package of the most interesting articles to help you stay at the top of your game.

  • NTAGI's technical sub-committee recommends use of Corbevax, Covaxin for children between 5-12 years Jul 08, 2022 05:44 PM IST

    NTAGI's technical sub-committee recommends use of Corbevax, Covaxin for children between 5-12 years

    Biological E’s Corbevax has been recommended for administration in 5 to 12 years old children, while the Bharat Biotech’s Covaxin has been recommended for children in 6-12 years’ age group.

  • COVID-19 shots administered in India about to overtake count in all of Europe, North America Jun 20, 2022 06:09 PM IST

    COVID-19 shots administered in India about to overtake count in all of Europe, North America

    This is a remarkable feat, considering that all the vaccine doses administered in the country are made locally

  • Covaxin proven safe for children of 2-18 years age group in phase III study: Bharat Biotech Jun 17, 2022 03:15 PM IST

    Covaxin proven safe for children of 2-18 years age group in phase III study: Bharat Biotech

    In a phase II/III research, Bharat Biotech International Ltd's COVID-19 vaccine Covaxin was found to be safe, well-tolerated, and highly immunogenic in children and adolescents aged 2 to 18 years.

  • Covaxin more effective for kids and adolescents than adults, Bharat Biotech publishes trial data Jun 17, 2022 11:14 AM IST

    Covaxin more effective for kids and adolescents than adults, Bharat Biotech publishes trial data

    The company said that no adverse events of special interest have been reported to date. However, a supplementary surveillance study is going on, which will provide more information on rarer adverse events

  • We are able to predict pandemic based on changes in virus, other signals: Bharat Biotech founder Jun 16, 2022 10:02 PM IST

    We are able to predict pandemic based on changes in virus, other signals: Bharat Biotech founder

    Bharat Biotech, the manufacturer of Covaxin, announced on Thursday that his business can now forecast a pandemic based on changes in viral and related signals.

  • Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study Jun 15, 2022 12:22 PM IST

    Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study

    The protective efficacy of Bharat Biotech's Covaxin following two and three-dose immuniszations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a Syrian hamster model (animal model to study human-associated diseases), it said.

  • Paraguay cancels order for one million Covaxin doses citing quality issues: Reports Jun 07, 2022 11:03 PM IST

    Paraguay cancels order for one million Covaxin doses citing quality issues: Reports

    Bharat Biotech did not immediately react to the development, but company sources reportedly said that all export orders already stand cancelled as the production has been halted.

  • Top virologists weigh in for Corbevax booster after primary vaccination with Covishield, Covaxin  Jun 06, 2022 01:30 PM IST

    Top virologists weigh in for Corbevax booster after primary vaccination with Covishield, Covaxin 

    The pharma regulator has approved the first mix-and-match of COVID-19 vaccines in India, but the final say-so lies with the government 

  • Germany to recognise Bharat Biotech’s Covaxin for travel from June 1 May 26, 2022 02:07 PM IST

    Germany to recognise Bharat Biotech’s Covaxin for travel from June 1

    German Ambassador to India and Bhutan, Walter J Lindner on Thursday said the government of the European nation will start recognizing Bharat Biotech’s COVID-19 vaccine for travel purpose there from June 1.

  • FDA lifts hold on Covaxin's clinical trials in US May 24, 2022 06:53 PM IST

    FDA lifts hold on Covaxin's clinical trials in US

    The FDA’s earlier decision, in April, to put on hold the trials was based on the US firm’s decision to voluntarily implement a temporary pause in dosing participants of the jab, following the World Health Organisation’s observations on Covaxin manufacturing plants in India.

  • Covid-19: 10 crore doses of SII's Covovax approved for exports by govt lab, stock rolled out for teens May 05, 2022 09:36 PM IST

    Covid-19: 10 crore doses of SII's Covovax approved for exports by govt lab, stock rolled out for teens

    Covovax, the Covid-19 vaccine manufactured by the Serum Institute of India under licence from US firm Novavax, will be available at Rs 225 per dose, excluding taxes, at private healthcare facilities.

  • Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old May 04, 2022 04:46 PM IST

    Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old

    Presently, precaution dose of Covaxin and Covishield is administered to all those aged above 18 who have completed nine months after the second dose.

  • Bharat Biotech must address WHO's Covaxin suspension to avoid EUL cancellation, says MEA Apr 28, 2022 07:51 PM IST

    Bharat Biotech must address WHO's Covaxin suspension to avoid EUL cancellation, says MEA

    In a communication to Dr V K Paul, the convenor of a key empowered group on COVID vaccination, on Tuesday the Ministry of External Affairs said many issues about vaccines and international travel by Indians have arisen and these must be addressed immediately.

  • Will wait for NTAGI’s nod before administering COVID-19 vaccine in 5-12 age group: Health Minister Apr 28, 2022 05:29 PM IST

    Will wait for NTAGI’s nod before administering COVID-19 vaccine in 5-12 age group: Health Minister

    When asked if the gap for taking the booster dose has been reduced from nine months to six, the minister said, NTAGI is the panel to take decisions in this regard.

  • COVID-19 vaccines for 5-11-year-olds may be limited to private hospitals  Apr 27, 2022 11:46 AM IST

    COVID-19 vaccines for 5-11-year-olds may be limited to private hospitals 

    Government approval for the administration of COVID-19 vaccines to children in the 5-11-year age group is possible as early as next week, according to health ministry officials familiar with the situation. 

  • Moneycontrol Selects: Top stories this evening Apr 26, 2022 07:43 PM IST

    Moneycontrol Selects: Top stories this evening

    Our specially curated package of the most interesting articles of the day will help you stay at the top of your game.

  • Covaxin approved for restricted emergency use in children aged 6-12 years Apr 26, 2022 01:02 PM IST

    Covaxin approved for restricted emergency use in children aged 6-12 years

    The regulator has asked Bharat Biotech to submit safety data, including the data on adverse event with due analysis, every 15 days for the first two months and monthly thereafter up to five months

  • India cuts dependency on imported raw material for drugs by 25%: Minister Mandaviya Apr 22, 2022 06:55 PM IST

    India cuts dependency on imported raw material for drugs by 25%: Minister Mandaviya

    India reduced imports by encouraging local production of key bulk drugs and offering manufacturers financial incentives.

  • US biotech firm Ocugen gets Covaxin rights for Mexico Apr 18, 2022 07:46 PM IST

    US biotech firm Ocugen gets Covaxin rights for Mexico

    The Mexican authorities have made conquering the COVID-19 pandemic a major priority, said Ocugen Inc co-founder and chief executive officer Dr Shankar Musunuri, adding that they met Mexico’s secretary of foreign affairs, Marcelo Ebrard, in Delhi.

  • Moneycontrol Daily: Your Essential 7 Apr 10, 2022 07:30 AM IST

    Moneycontrol Daily: Your Essential 7

    A daily round-up of the most interesting articles to help jump-start the day.

Sections
ISO 27001 - BSI Assurance Mark